Australia seems poised to experience a groundbreaking therapy for excess weight: Retatrutide. This dual agonist – targeting on both GLP-1 and GIP receptors – shows promising outcomes in clinical trials, indicating substantial decreases in weight. While regulatory clearance hasn't occurred with th